阿德福韦联合拉米夫定治疗慢性乙型肝炎患者临床观察

doi:10.3969/j.issn.1672-5069.2014.05.022

Abstract

Ren Tao, Xu Li, Huan Hui. Adefovir combined with lamivudine in treatment of patients with HBeAg-positive hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 531-532.

[1] 郭明日, 吴敏, 张立, 等.乙型肝炎血清学标志物与HBV DNA定量及肝功能指标相关性研究. 国际检验医学杂志,2013,34（18）:2465-2466.
[2] Cholongitas E,Goulis J,Akriviadis E,et a1.Hepatitis B immunoglobulin and/or nucleos（t）ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation:a systematic review. Liver Transpl,2011,17（10）:1176-1190.
[3] 胡侠, 王开鉴. 联合拉米夫定继续治疗阿德福韦酯初治HBeAg阳性慢性乙型肝炎不应答患者3年疗效观察.实用肝脏病杂志, 2013,16（4）:308-309.
[4] Gane EJ,Patterson S,Strasser SI,et a1.Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl,2013,19（3）:268-274.
[5] 邹立新, 陈兰, 魏中华, 等. 慢性乙型肝炎治疗过程中实验指标动态观察. 重庆医学,2009,38（1）:64-67.
[6] 任方元,李小丹. 阿德福韦酯联合拉米夫定治疗拉米夫定耐药的 HBeAg 阳性慢性乙型肝炎患者临床疗效观察. 实用肝脏病杂志,2014,17（2）：141-144.
[7] Lok AS,Trinh H,Carosi G,et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos（t）ide-naive patients with chronic hepatitis B. Gastroenterology,2012,143（3）:619-628.
[8] 黄利坚, 洪昱钤,徐振兴,等.阿德福韦酯治疗代偿期乙型肝炎肝硬化5年疗效观察. 实用肝脏病杂志,2013,16（1）：73.
[9] 张建春. 拉米夫定和阿德福韦酯初始联合与恩替卡韦单药治疗高病毒载量慢性乙型肝炎疗效观察.中华临床感染病杂志,2012,5（3）：142-144.
[10] Güzelbulut F,Ovünc AO,Oetinkaya ZA,et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.Gastroenterology,2012,59（114）:477-480.
[11] 严海明, 陈建华,叶一农,等.拉米夫定联合阿德福韦酯治疗与恩替卡韦单药治疗HBeAg阳性慢性乙型肝炎患者48周疗效比较. 实用肝脏病杂志,2013,29（7）：508-511.
[12] Dogan UB,Kara B,Gümürdülü Y,et al. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos（t）ide-naive patients with chronic hepatitis B. Turk J Gastroenterol,2012,23（3）:247-252.
[13] 宋伟泉,徐尧江,张要栋,等.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗失代偿期乙型肝炎肝硬化二年疗效比较.中华临床感染病杂志,2012,5（3）：137-141.
[14] Keating GM.Entecavir:a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs,2011,71（18）:2511-2529.
[15] Singal AK,Fontana RJ.Meta-analysis:oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther,2012,35（6）:674-689.

Adefovir combined with lamivudine in treatment of patients with HBeAg-positive hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.